MIZOLASTINE IN THE TREATMENT OF ALLERGIC RHINITIS AND URTICARIA

Among the vast variety of clinical studies submitted, mizolastine prov es to be a highly selective antagonist for histamine H-1 receptors wit h a rapid onset of action and long-lasting effect in the treatment of seasonal and perennial allergic rhinitis and pruritus and urticaria. T he once-daily dosage of 10 mg Mizolastine improves patient compliance. Mizolastine suppresses weal and flare reactions rapidly and consisten tly and also exhibits anti-inflammatory and leukotrien-antagonistic pr operties. With respect to efficacy, Mizolastine was at least equal to other second-generation antihistamines and showed additional beneficia l effects on nasal obstruction. Side effects such as sedation, impairm ent of psychomotor performance, cognitive functions and driving skills as well as cardiotoxic effects did not occur more frequently with the rapeutic doses of Mizolastine than with placebo. Due to its low incide nce of side effects and good clinical effectiveness, the new antihista mine, Mizolastine, constitutes a true alternative among the spectrum o f antiallergic therapeutics. Its pronounced additional anti-inflammato ry properties prove to be a promising starting point in the treatment of conditions with perennial allergic rhinitis with ''nasal obstructio n'' as the prominent symptom.